Migdal Insurance & Financial Holdings Ltd. Editas Medicine, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$7.12 Billion
Q1 2025

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 04, 2021	SELL	$31.29 - $56.64 $638,535 - $1.16 Million	-20,407 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$39.71 - $90.58 $810,361 - $1.85 Million	20,407 New	20,407 $857,000

Others Institutions Holding EDIT

# of Institutions

218

Shares Held

47.9M

Call Options Held

436K

Put Options Held

324K

Black Rock Inc. New York, NY

7.78M
Shares

$12.8 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

7.47M
Shares

$12.2 Million
0.0% of portfolio
Morgan Stanley New York, NY

2.66M
Shares

$4.36 Million
0.0% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

2.6M
Shares

$4.26 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.94M
Shares

$3.19 Million
0.0% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $113M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account